Get the Stockscreener App
18.81
0.37%
-0.07
After Hours:
18.81
Monte Rosa Therapeutics Inc stock is traded at $18.81, with a volume of 891.22K.
It is down -0.37% in the last 24 hours and down -10.34% over the past month.
Monte Rosa Therapeutics Inc is a clinical-stage biotechnology company that specializes in developing molecular glue degraders (MGDs), a class of small molecule drugs that leverage the body's natural protein destruction mechanisms to selectively degrade therapeutically-relevant proteins. Utilizing the QuEEN platform, the company employ artificial intelligence and proprietary experimental tools to identify target proteins for degradation by MGDs. The company has three programs in clinical development: MRT-6160, a VAV1-directed MGD for immune-mediated diseases; MRT-8102, a NEK7-directed MGD for inflammatory diseases driven by IL-6, and the NLRP3 inflammasome; and MRT-2359, a GSPT1-directed MGD for metastatic castration resistant prostate cancer (mCRPC).
See More
Previous Close:
$18.88
Open:
$18.72
24h Volume:
891.22K
Relative Volume:
0.90
Market Cap:
$1.59B
Revenue:
$123.67M
Net Income/Loss:
$-38.63M
P/E Ratio:
-30.49
EPS:
-0.617
Net Cash Flow:
$-27.50M
1W Performance:
+3.64%
1M Performance:
-10.34%
6M Performance:
+32.28%
1Y Performance:
+364.44%
1-Day Range:
$18.45
$19.79
1-Week Range:
$17.43
$19.79
52-Week Range:
$3.90
$25.77
Monte Rosa Therapeutics Inc Stock (GLUE) Company Profile
Name
Monte Rosa Therapeutics Inc
Sector
Industry
Phone
617-949-2643
Address
321 HARRISON AVENUE, BOSTON
Compare GLUE vs VRTX, REGN, ARGX, ALNY, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
GLUE
Monte Rosa Therapeutics Inc
|
18.81 | 1.59B | 123.67M | -38.63M | -27.50M | -0.617 |
VRTX
Vertex Pharmaceuticals Inc
|
434.52 | 110.03B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
638.88 | 67.37B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
806.46 | 50.76B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
297.45 | 40.12B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
151.56 | 32.68B | 742.00K | -1.37B | -1.07B | -7.0731 |
Monte Rosa Therapeutics Inc Stock (GLUE) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-19-24 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| Feb-15-24 | Initiated | Wedbush | Outperform |
| Jan-03-23 | Upgrade | Wells Fargo | Equal Weight → Overweight |
| Oct-13-22 | Initiated | UBS | Buy |
| Aug-15-22 | Initiated | Jefferies | Buy |
| Apr-28-22 | Initiated | Credit Suisse | Neutral |
| Feb-10-22 | Initiated | Wells Fargo | Equal Weight |
| Oct-14-21 | Initiated | SVB Leerink | Mkt Perform |
View All
Monte Rosa Therapeutics Inc Stock (GLUE) Latest News
Monte Rosa Therapeutics director sells $180,100 of Glue shares By Investing.com - Investing.com Canada
Monte Rosa Therapeutics director sells $180,100 of Glue shares - Investing.com
Monte Rosa Therapeutics (GLUE) director exercises options and sells 10K shares - Stock Titan
[144] Monte Rosa Therapeutics, Inc. SEC Filing - Stock Titan
GLUE Technical Analysis | Trend, Signals & Chart Patterns | MONTE ROSA THERAPEUTICS INC (NASDAQ:GLUE) - ChartMill
IDEA Pharma recognizes Monte Rosa Therapeutics for advancing MGD drug development - Traders Union
Monte Rosa Therapeutics to Participate in Upcoming Investor Conferences - The Manila Times
Biotech Monte Rosa lines up TD Cowen and Jefferies investor talks - Stock Titan
Vanguard Group Inc. Has $50.91 Million Position in Monte Rosa Therapeutics, Inc. $GLUE - MarketBeat
Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE) Given Average Recommendation of "Moderate Buy" by Analysts - MarketBeat
Monte Rosa Therapeutics (GLUE) — TCG/Chen Yu report 5.5% holding - Stock Titan
[SCHEDULE 13G/A] Monte Rosa Therapeutics, Inc. Amended Passive Investment Disclosure - Stock Titan
BVF Group (GLUE) entities report up to 5.09M shares, 6.3% total - Stock Titan
Analysts Offer Insights on Healthcare Companies: Intellia Therapeutics (NTLA) and Perspective Therapeutics (CATX) - The Globe and Mail
Monte Rosa Therapeutics (NASDAQ:GLUE) Given New $31.00 Price Target at JPMorgan Chase & Co. - MarketBeat
J.P. Morgan Maintains Monte Rosa Therapeutics(GLUE.US) With Buy Rating, Raises Target Price to $31 - Moomoo
Monte Rosa Therapeutics to detail new molecular glue degrader research at Endpoints webinar - Traders Union
Monte Rosa Therapeutics (NASDAQ:GLUE) Issues Quarterly Earnings Results, Misses Estimates By $0.06 EPS - MarketBeat
Monte Rosa Trial Progress And Valuation Gap Draw Investor Attention - Yahoo Finance
Monte Rosa Therapeutics (GLUE) reports Q1 loss, misses revenue estimates - MSN
Wedbush Maintains Monte Rosa Therapeutics(GLUE.US) With Buy Rating, Maintains Target Price $37 - Moomoo
Piper Sandler Maintains Monte Rosa Therapeutics(GLUE.US) With Buy Rating, Maintains Target Price $37 - Moomoo
Wall Street Analysts Are Bullish on Top Healthcare Picks - The Globe and Mail
TD Cowen Maintains Monte Rosa Therapeutics(GLUE.US) With Buy Rating - Moomoo
Monte Rosa Therapeutics 1Q Research and Development Expenses $44.1M >GLUE - Moomoo
10 Health Care Stocks Whale Activity In Today's Session - Sahm
Monte Rosa Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026 - marketscreener.com
Monte Rosa Therapeutics Announces First Quarter 2026 Financial Results and Business Updates - Investing News Network
Monte Rosa Therapeutics (GLUE) Reports Q1 Loss, Misses Revenue Estimates - Yahoo Finance
Monte Rosa Therapeutics Inc (NASDAQ:GLUE) Reports Q1 2026 Results as Clinical Progress Drives Focus on Upcoming Catalysts - ChartMill
MONTE ROSA THERAPEUTICS ($GLUE) Releases Q1 2026 Earnings - Quiver Quantitative
Monte Rosa Therapeutics Inc reports results for the quarter ended March 31Earnings Summary - TradingView
Monte Rosa Therapeutics: Q1 Earnings Snapshot - marketscreener.com
Earnings Flash (GLUE) Monte Rosa Therapeutics, Inc. Reports Q1 Revenue $4.2M, vs. FactSet Est of $11.4M - marketscreener.com
Monte Rosa Therapeutics 1Q 2026: Revenue $4.21M, EPS $(0.45) — 10-Q Summary - TradingView
Monte Rosa (NASDAQ: GLUE) swings to Q1 loss but extends cash runway into 2029 - Stock Titan
Earnings Flash (GLUE) Monte Rosa Therapeutics, Inc. Reports Q1 Revenue $4.2M, Vs. FactSet Est of $11.4M - Moomoo
Biotech Monte Rosa says its $671M cash pile funds operations into 2029 - Stock Titan
Monte Rosa (NASDAQ: GLUE) swings to Q1 2026 loss, builds cash runway into 2029 - Stock Titan
GLUE earnings ahead: Can Monte Rosa rebound from revenue miss? By Investing.com - Investing.com Australia
GLUE earnings ahead: Can Monte Rosa rebound from revenue miss? - Investing.com India
Monte Rosa Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Planned Monte Rosa (GLUE) CEO share sale under Rule 10b5-1 - Stock Titan
GLUE Forecast, Price Target & Analyst Ratings | MONTE ROSA THERAPEUTICS INC (NASDAQ:GLUE) - ChartMill
Dunn Edmund, principal accounting officer, sells Monte Rosa (GLUE) shares for $2496 - Investing.com
Form 144 | Monte Rosa Therapeutics(GLUE.US) Officer Proposes to Sell 103.45 Million in Common Stocks - Moomoo
Monte Rosa Therapeutics (GLUE) Form 144: RSU 21,865; Markus Warmuth sales listed - Stock Titan
GLUE SEC FilingsMonte Rosa Therapeutics, Inc. 10-K, 10-Q, 8-K Forms - Stock Titan
Monte Rosa Therapeutics (GLUE) Projected to Post Quarterly Earnings on Thursday - MarketBeat
Short Interest in Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE) Expands By 18.2% - MarketBeat
Monte Rosa Therapeutics | DEF 14A: Definitive information statements - Moomoo
Monte Rosa Therapeutics Inc Stock (GLUE) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.98%
1.33%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):